Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  American Journal of Neurodegenerative Disease

• Publication date

  2012-11-21

• Fields of study

  Medicine

• Identifiers
  PMID 23383400PMCID PMC3560466
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hitting a complex target: an update on interleukin-6 trans-signalling

  2012cited by this paper
• Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1.

  2012cited by this paper
• Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS.

  2012cited by this paper
• The role of tocilizumab in the management of rheumatoid arthritis

  2012cited by this paper
• Integrated safety in tocilizumab clinical trials

  2011cited by this paper
• The value of blocking IL-6 outside of rheumatoid arthritis: current perspective

  2011cited by this paper
• Inhibition of Classic Signaling Is a Novel Function of Soluble Glycoprotein 130 (sgp130), Which Is Controlled by the Ratio of Interleukin 6 and Soluble Interleukin 6 Receptor*

  2011cited by this paper
• The pro- and anti-inflammatory properties of the cytokine interleukin-6.

  2011cited by this paper
• A meta-analysis of cytokines in Alzheimer's disease.

  2010cited by this paper
• Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions

  2010cited by this paper
• IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients

  2010cited by this paper
• Mutant superoxide dismutase 1-induced IL-1β accelerates ALS pathogenesis

  2010cited by this paper
• IL-17 and Th17 Cells.

  2009cited by this paper
• Therapeutic Targeting of IL-6 Trans Signaling Counteracts STAT3 Control of Experimental Inflammatory Arthritis1

  2009cited by this paper
• Interleukin-17 and type 17 helper T cells.

  2009cited by this paper
• Development of rabbit monoclonal and polyclonal antibodies for detection of site-specific histone modifications and their application in analyzing overall modification levels

  2006cited by this paper
• Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells

  2004cited by this paper
• Presence of dendritic cells, MCP‐1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue

  2004cited by this paper
• Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease.

  1998cited by this paper
• The therapeutic potential of interleukin-6 hyperagonists and antagonists.

  1997cited by this paper
• Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients.

  1997cited by this paper
• Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients

  1995cited by this paper
• Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

  1995cited by this paper

• Schwann cells as a therapeutic target for Amyotrophic Lateral Sclerosis: A TDP-43 Focussed Review.

  2025cites this paper
• Antibody targeting TDP-43 mitigates pathogenic pathways induced by the cerebrospinal fluid of ALS

  2025cites this paper
• OPTN protects retinal ganglion cells and ameliorates neuroinflammation in optic neuropathies

  2025influential citation
• Neuroinflammation and Amyotrophic Lateral Sclerosis: Recent Advances in Anti-Inflammatory Cytokines as Therapeutic Strategies

  2025cites this paper
• Enhanced Interleukin 6 Trans-Signaling Modulates Disease Process in Amyotrophic Lateral Sclerosis Mouse Models

  2025cites this paper
• The Role of IL-6 in Neurodegenerative Disorders

  2024cites this paper
• ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS

  2024cites this paper
• Intrathecal tocilizumab for immune-mediated central nervous system complication after haploidentical hematopoietic stem cell transplantation in children: Two case reports

  2024cites this paper
• The Current Landscape of Hypotheses Describing the Contribution of CD4+ Heterogeneous Populations to ALS

  2024cites this paper
• Endogenous retroviruses are dysregulated in ALS

  2024cites this paper
• The multifaceted role of the CXC chemokines and receptors signaling axes in ALS pathophysiology.

  2024cites this paper
• CSF oligoclonal IgG bands are not associated with ALS progression and prognosis

  2023cites this paper
• Novel therapeutic approaches for motor neuron disease.

  2023cites this paper
• The Molecular Link Between TDP-43, Endogenous Retroviruses and Inflammatory Neurodegeneration in Amyotrophic Lateral Sclerosis: a Potential Target for Triumeq, an Antiretroviral Therapy

  2023cites this paper
• Network Pharmacology and Molecular Docking to Unveil the Mechanism of Shudihuang Against Amyotrophic Lateral Sclerosis.

  2023cites this paper
• Autoimmune Neuroinflammatory Diseases: Role of Interleukins

  2023cites this paper
• Advances on Cellular Clonotypic Immunity in Amyotrophic Lateral Sclerosis

  2022cites this paper
• Screening Immunotherapy Targets to Counter Radiation-Induced Neuroinflammation

  2022cites this paper
• Therapeutic Benefit in Rheumatoid Cachexia Illustrated Using a Novel Primary Human Triple Cell Coculture Model

  2022cites this paper
• Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis

  2022cites this paper
• Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis

  2022cites this paper
• Repositioned Drugs for COVID-19—the Impact on Multiple Organs

  2021cites this paper
• Neuroinflammation in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia and the Interest of Induced Pluripotent Stem Cells to Study Immune Cells Interactions With Neurons

  2021cites this paper
• Monocyte CD14 and HLA-DR expression increases with disease duration and severity in amyotrophic lateral sclerosis

  2021cites this paper
• Can rheumatologists stop causing demyelinating disease?

  2021cites this paper
• Tocilizumab is safe and tolerable and reduces C‐reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients

  2021cites this paper
• Antibody-Based Therapeutic Interventions for Amyotrophic Lateral Sclerosis: A Systematic Literature Review

  2021influential citation
• Interleukin 6 (IL6) level is a biomarker for functional disease progression within IL6R358Ala variant groups in amyotrophic lateral sclerosis patients

  2020cites this paper
• A bioinformatics approach revealed the transcription factors of Helicobacter pylori pathogenic genes and their regulatory network nodes

  2020cites this paper
• Chitotriosidase, a biomarker of amyotrophic lateral sclerosis, accentuates neurodegeneration in spinal motor neurons through neuroinflammation

  2020cites this paper
• Immune Gene Data-based Molecular Subtyping of Rectal Adenocarcinoma Related to Prognosis

  2020cites this paper
• Research on active compounds regarding SGMD for the treatment of COVID-19 based on network pharmacology and molecular docking

  2020cites this paper
• Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes

  2020cites this paper
• The Peripheral Immune System and Amyotrophic Lateral Sclerosis

  2020cites this paper
• Very Early Involvement of Innate Immunity in Peripheral Nerve Degeneration in SOD1-G93A Mice

  2020cites this paper
• Interleukin-36γ–producing macrophages drive IL-17–mediated fibrosis

  2019cites this paper
• Targeting Macrophage for the Treatment of Amyotrophic Lateral Sclerosis.

  2019cites this paper
• ALS blood expression profiling identifies new biomarkers, patient subgroups, and evidence for neutrophilia and hypoxia

  2019cites this paper
• Single cell RNA-seq in regenerative and fibrotic biomaterial environments defines new macrophage subsets

  2019cites this paper
• IL6 receptor358Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis

  2019cites this paper
• Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction.

  2018cites this paper
• Inflammation, immunity, and amyotrophic lateral sclerosis: II. immune‐modulating therapies

  2018cites this paper
• The development of biological therapies for neurological diseases: moving on from previous failures

  2018cites this paper
• Angiopoietin-1 and ανβ3 integrin peptide promote the therapeutic effects of L-serine in an amyotrophic lateral sclerosis/Parkinsonism dementia complex model

  2018cites this paper
• A Possible Role for Platelet-Activating Factor Receptor in Amyotrophic Lateral Sclerosis Treatment

  2018cites this paper
• Inflammatory role of dendritic cells in Amyotrophic Lateral Sclerosis revealed by an analysis of patients’ peripheral blood

  2017cites this paper
• Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic Implications

  2017cites this paper
• Blood–Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies

  2017cites this paper
• Immunoregulatory effect of mast cells influenced by microbes in neurodegenerative diseases.

  2017cites this paper
• Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis

  2017cites this paper
• Therapeutic Strategies Under Development Targeting Inflammatory Mechanisms in Amyotrophic Lateral Sclerosis

  2017cites this paper
• Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials

  2017cites this paper
• Management and therapeutic perspectives in amyotrophic lateral sclerosis

  2017cites this paper
• Activation state and functionality of dendritic cells from peripheral blood of amyotrophic lateral sclerosis patients

  2017cites this paper
• Interleukin-6 Deficiency Does Not Affect Motor Neuron Disease Caused by Superoxide Dismutase 1 Mutation

  2016cites this paper
• Therapeutic progress in amyotrophic lateral sclerosis-beginning to learning.

  2016cites this paper
• Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis

  2016cites this paper
• Combined Metabolomics and Transcriptomics Approaches to Assess the IL-6 Blockade as a Therapeutic of ALS: Deleterious Alteration of Lipid Metabolism

  2016cites this paper
• Identification of amyotrophic lateral sclerosis disease mechanisms by cerebrospinal fluid proteomic profiling

  2016cites this paper
• Tocilizumab and multiple sclerosis: a causal relationship? Clinical Commentary on the case report entitled – MS arising during Tocilizumab therapy for rheumatoid arthritis

  2016cites this paper
• Tocilizumab’s effect on cognitive deficits induced by intracerebroventricular administration of streptozotocin in Alzheimer’s model

  2016cites this paper
• Dysregulated Lysine Acetyltransferase 2B Promotes Inflammatory Bowel Disease Pathogenesis Through Transcriptional Repression of Interleukin-10.

  2016cites this paper
• Targeting miR‐155 restores abnormal microglia and attenuates disease in SOD1 mice

  2015cites this paper
• Therapeutic development in amyotrophic lateral sclerosis.

  2015cites this paper
• Review Article Therapeutic Development in Amyotrophic Lateral Sclerosis

  2015cites this paper
• New kid on the block: does histamine get along with inflammation in amyotrophic lateral sclerosis?

  2015cites this paper
• Transcriptional analysis reveals distinct subtypes in amyotrophic lateral sclerosis: implications for personalized therapy.

  2015cites this paper
• Use of biomarkers in ALS drug development and clinical trials.

  2015cites this paper
• Chronic systemic IL-1β exacerbates central neuroinflammation independently of the blood-brain barrier integrity.

  2015cites this paper
• Complex Inflammation mRNA-Related Response in ALS Is Region Dependent

  2015cites this paper
• Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis

  2015cites this paper
• Anti-inflammatory therapies of amyotrophic lateral sclerosis guided by immune pathways.

  2015cites this paper
• Applications and Implications of Heparin and Protamine in Tissue Engineering and Regenerative Medicine

  2014cites this paper
• NP001 regulation of macrophage activation markers in ALS: A phase I clinical and biomarker study

  2014cites this paper
• Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis

  2014cites this paper
• Tocilizumab infusion therapy normalizes inflammation in sporadic ALS patients.

  2013influential citation